CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:MHC class II regulation of CD8(+) T cell tolerance and implications in autoimmunity and cancer immunotherapy.
MHC class II regulation of CD8(+) T cell tolerance and implications in autoimmunity and cancer immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
主要组织相容性复合体(MHC)II类反应性CD8+ T细胞存在于人类和动物中,但对其身份、发育和功能知之甚少。在本研究中,我们在MHC II类缺陷小鼠中发现了一群同时对MHC I类和II类分子反应的CD8+ T细胞。我们克隆了它们的T细胞受体(TCR),并分析了它们的发育和功能。在野生型动物中,携带这些TCR的胸腺细胞通过阴性选择被清除。在缺乏MHC II类的情况下,它们发育为成熟的CD8+ T细胞。当在外周遇到MHC II类分子时,它们发生强烈的激活和增殖,攻击自身组织,并导致致死性自身免疫疾病。在过继性T细胞治疗中,这些CD8+ T细胞能够有效控制表达MHC II类分子的肿瘤。本研究为研究双重反应性CD8+ T细胞、它们在胸腺中的发育和选择,以及当其正常发育和选择受到破坏时的危险与希望打开了大门。
Major histocompatibility complex (MHC) class II-reactive CD8 + T cells are found in humans and animals, but little is known about their identity, development, and function. In this study, we discover a group of CD8 + T cells reactive to both MHC class I and II molecules in MHC class II-deficient mice.
We clone their T cell receptors (TCRs) and analyze their development and function. In wild-type animals, thymocytes bearing those TCRs are purged by negative selection. In the absence of MHC class II, they develop into mature CD8 + T cells. When encountering MHC class II in the periphery, they undergo robust activation and proliferation, attack self-tissues, and cause lethal autoimmune diseases. In adoptive T cell therapy, those CD8 + T cells are able to efficiently control MHC class II-expressing tumors.
This study opens the door to investigation of dual-reactive CD8 + T cells, their development and selection in the thymus, and the perils and promises when their normal development and selection are compromised.
MEMBER ACCOUNT
登录成功会直接打开下一页。